Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference25 articles.
1. Chao EC, Henry RR. SGLT2 inhibition—a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–9.
https://doi.org/10.1038/nrd3180
.
2. De P, Child DF. Euglycaemic diabetic ketoacidosis—is it on the rise? Pract Diabetes Int. 2001;18:239–40.
3. Rjf E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638–42.
4. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512–7.
https://doi.org/10.1038/nm.3828
.
5. Kitabchi AE, Hirsch IB, Emmet M. Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: clinical features, evaluation, and diagnosis. In: Post TW, editor. UpToDate. Waltham: UpToDate; 2018.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献